Precision oncology, interpreted in context
From fragmented cancer data to one clear clinical direction.
Dr PreZiGen connects the right experts, AI-assisted evidence synthesis and patient-specific context — turning complexity into a clear, responsible precision-oncology opinion for you and your treating team.
AI intelligence × Human judgement
Evidence-linked · Patient-specific · Expert-reviewed
When experts connect, complexity becomes clarity
Different disciplines. One clinical question. One evidence-linked direction for the patient.
Oncology, pathology, genomics, computational biology and evidence science work together as one connected intelligence system.
- Medical oncology
- Pathology
- Radiology
- Genomics
- Computational biology
- Evidence science
Choose your pathway
Start with who you are. We will guide the next step.
- Clinicians Patient-specific interpretation and expert consultation. Explore solutions
- Hospitals Virtual Molecular Tumor Board and centre-of-excellence workflows. Explore solutions
- Patients Clear explanations for informed conversations with your care team. Explore solutions
- Diagnostics Clinical-context interpretation that adds value to NGS. Explore solutions
- Biopharma Biomarker strategy, education and responsible adoption. Explore solutions
The decision-ready output
Not another data dump. A decision-ready answer.
A concise clinical snapshot connects the patient journey, molecular drivers, possible resistance biology, evidence tiers, treatment considerations, trials and expert review — prepared for discussion with the treating team.
- Clinical context
- Molecular portrait
- Evidence ladder
- Expert sign-off
Dr PreZiGen · Sample interpretation format
Precision oncology snapshot
Integrated molecular interpretation
Clinical question
Which molecular findings are clinically relevant, and what additional evidence should inform the next discussion with the treating team?
| Finding | Biological role | How it is framed |
|---|---|---|
| Driver alteration (example) | Oncogenic signalling | Evidence tier and source cited |
| Tumour-suppressor change | Loss of growth control | Context and uncertainty stated |
| Co-occurring finding | Possible resistance marker | Flagged for expert discussion |
Evidence-linked considerations
- Established
- Alternative
- Clinical trial
- Further testing
How it works
AI organises the evidence. Accountable experts interpret it.
- Choose your pathway and tell us what you need answered. Clinical documents are uploaded only inside the secure portal.
Evidence is organised
AI-assisted tools help sort reports into a timeline and map findings against published evidence.Experts review
Qualified specialists add clinical context, reasoning and uncertainty, and sign off the opinion.Your team decides
You receive a clear, referenced summary to discuss with the treating team, who make the final decisions.
Voice of experience
Verified patient and clinician experiences will appear here.
We only publish experiences that are genuine, verified and shared with explicit consent.
Secure case workflow
Ready to bring clarity to a complex case?
Patients and families, clinicians, hospitals, diagnostic centres and biopharma partners each have a dedicated, secure starting point.
Secure · Clinical documents are uploaded only after you sign in to the portal